NEWCASTLE UNDER LYME, UK, April 18 /PRNewswire-FirstCall/ -- Traxxec Ltd, the UK subsidiary of Columbia River Resources Inc (Pink Sheets OTC - CRVR.pk), has opened new sales channels selling directly to the clinical trial and contract market.
As part of the tertiary stage of its re-organisation the Company has negotiated a policy with Rexam plc that allows it to sell directly in to the pharmaceutical clinical trial arena and to pharmaceutical contract and clinical research organisations. These are market sectors in which Traxxec holds considerable expertise. Initially offering lower volumes per contract, the sales are more suited to the approach of a systems integration company such as Traxxec. With licenced partner Rexam focusing on volume sales to the high volume manufacturing facilities, Traxxec can bring additional sales by expanding the new channels.
It has been reported previously that Traxxec has already implemented pilot studies and directly supplied product in this arena both in the US and in Europe. The companies feel that the most efficient way to leverage the opportunity is to ensure 'first to market' status, establish a market share and continually stay one step ahead through evolution and innovation of the product concept.
Product development is now complete, IP protected and manufacturing out-licensed by agreement. Key focus for the coming quarter will be efficiency and volume of new and existing routes to market. Traxxec has the necessary expertise and knowledge to deliver infrastructure solutions, allowing the new direct sales channels to include the possible sale, design and implementation of systems to the end user is outside of the license agreement with Rexam.
CEO Amy Scopes comments "With previous experience of supplying packaging systems expertise to companies such as Glaxo Smith Kline and AstraZeneca and Pfizer we are delighted open up these new sales channels. They represent a specialist sector of our business expansion plan and revenue generation. We believe our previous strong performance in this arena will be of significant benefit in the expansion of this sector".
Columbia River Resources Inc will be filing to change the corporate name to Traxxec Inc as the completion of its reorganisation.
For more information please visit http://www.traxxec.com/ NOTES: 1. Traxxec's technology has worldwide patent protection 2. As part of the proposed business model and product development process the founders of Traxxec, funded by the pharmaceutical industry, have undertaken through two pilot installations a feasibility study on product design and as a consequence of this work, supplied a fully commercial product for evaluation purposes to a client with an annual buying capacity of 20,000,000 bottles. Traxxec Ltd was incorporated specifically to exploit this IP commercially. Since its incorporation, Traxxec Ltd has also supplied commercial product for a live, current phase III study in the US. As part of the technology transfer to Rexam Pharma, commercial product was successfully manufactured by them and supported by systems software provided by Traxxec Ltd. To date 21,000 units have been delivered. 3. The result of the comprehensive testing led to the decision by Rexam to enter into licensing negotiation and complete the 15 year royalty licence agreement. The market sector for pharmaceutical product is in excess of 20 billion US dollars and bottles represent 30% of the available market per annum. 4. Traxxec has commercial arrangements with Assa Abloy identification Technologies, a Swiss based global leader in the supply of packaged RFID component parts and with Telsonic Ultrasonics for current and further product development work. 5. With the global patent and the relationship with Rexam, its first licence contract, the company is ideally positioned to deliver this potential within this very lucrative market, with revenues from both product sales and system integrations as well as revenues form any further development products in line with its business model.
For further information on Traxxec's developments within the RFID/packaging industry please visit the articles below.
http://www.in-pharmatechnologist.com/news/ng.asp?id=73668-rexam-traxxec- rfid-fda-pill-container
http://www.modplas.com/inc/mparticle.php?section=E-Weekly&thefilename= eweekly07012007_22
http://www.ceepackaging.com/2007/01/24/rfid-solution-for-containers/ http://rfid.idtechex.com/knowledgebase/en/sectionintro.asp?sectionid=115 http://www.packaging-gateway.com/features/feature1317/ http://www.rexam.com/files/pdf/fce_presskit.pdf
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. The words "estimate," "project," "intends," "expects," "believes," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbour" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made and the Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.
